aav-vector-design-agent — independently scanned and version-tracked by SaferSkills.
SaferSkills independently audited aav-vector-design-agent (Agent Skill) and scored it 100/100 (green). The audit ran 55 deterministic rules across Security, Supply Chain, Maintenance, Transparency, and Community; it found 0 high-severity and 0 lower-severity findings. The full rule-by-rule trace and per-finding evidence are below. Free, methodology-open.
Findings & checks · 0 flagged
Every scanned point with the score it earned and what moved between them.
First recorded scan — no prior version to compare against.
The primary manifest — the file an agent reads to learn what this artifact does.
The AAV Vector Design Agent provides AI-driven design of adeno-associated virus vectors for gene therapy applications. It covers capsid selection and engineering, promoter/enhancer design, transgene optimization, and manufacturing considerations.
| Serotype | Primary Tropism | Clinical Use |
|---|---|---|
| AAV1 | Muscle, CNS | Glybera (muscle) |
| AAV2 | Broad (liver, muscle) | Luxturna (retina) |
| AAV5 | CNS, liver, retina | Hemgenix (liver) |
| AAV8 | Liver, muscle | Multiple trials |
| AAV9 | CNS, cardiac, liver | Zolgensma (CNS) |
| AAVrh10 | CNS, liver | CNS trials |
| AAVrh74 | Muscle | Elevidys (muscle) |
| AAV-PHP.eB | CNS (mouse) | Research |
User: "Design an AAV vector for liver-directed gene therapy in hemophilia B with low immunogenicity."
Agent Action:
python3 Skills/Gene_Therapy/AAV_Vector_Design_Agent/aav_designer.py \
--target_tissue liver \
--therapeutic_gene F9 \
--indication hemophilia_b \
--minimize_immunogenicity true \
--nab_escape true \
--promoter liver_specific \
--output aav_design/5' ITR - [Promoter] - [5' UTR] - [Transgene] - [WPRE] - [PolyA] - 3' ITR
Packaging limit: ~4.7 kb between ITRsPromoter Options:
| Promoter | Type | Size | Application |
|---|---|---|---|
| CAG | Ubiquitous | 1.7 kb | Strong expression |
| EF1α | Ubiquitous | 1.2 kb | Constitutive |
| LP1 | Liver-specific | 0.5 kb | Hepatocyte targeting |
| hSyn | Neuron-specific | 0.5 kb | CNS applications |
| MCK | Muscle-specific | 0.6 kb | Myopathies |
| CMV | Ubiquitous | 0.6 kb | High initial (silenced) |
Directed Evolution:
Rational Design:
Machine Learning:
Pre-existing NAbs:
| Serotype | NAb Prevalence |
|---|---|
| AAV2 | 30-60% |
| AAV5 | 15-30% |
| AAV8 | 15-25% |
| AAV9 | 20-35% |
Mitigation Strategies:
Tropism Prediction:
Immunogenicity Modeling:
Expression Optimization:
| Factor | Impact | Optimization |
|---|---|---|
| Capsid yield | Production cost | Sequence modifications |
| Empty/full ratio | Potency | Purification method |
| Aggregation | Stability | Formulation |
| DNA packaging | Transgene size | Cassette design |
AI Group - Biomedical AI Platform
~30 seconds. Free. No account. Every finding cites a rule and a line of evidence.